Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China

Acute myeloid leukaemia (AML) is the most common form of acute leukaemia in adults, with increasing incidence with age and a generally poor prognosis. Almost 20% of AML patients express mutant isocitrate dehydrogenase 2 (mIDH2), which leads to the accumulation of the carcinogenic metabolite 2-hydrox...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Zhiqiang Wang, Zhibo Zhang, Yong Li, Li Sun, Dezhen Peng, Danyu Du, Xian Zhang, Luwei Han, Liwen Zhao, Ligong Lu, Hongzhi Du, Shengtao Yuan, Meixiao Zhan
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Elsevier 2021-06-01
سلاسل:	Acta Pharmaceutica Sinica B
الموضوعات:	Acute myeloid leukaemia Tumor metabolism Mutant isocitrate dehydrogenase 2 (mIDH2) mIDH2 inhibitor SH1573 2-Hydroxyglutarate
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2211383521000769
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!